Inhibiting Lactylation‐Mediated Metabolic‐Epigenetic Reprogramming to Potentiate Tumor Photo‐Immunotherapy
Advanced Healthcare Materials · 05.11.2026
DOI: 10.1002/adhm.71955 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 05.11.2026. Verfasst von Ziqun Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Separation Membrane Materials, School of Chemistry & School of Electronics and Information Engineering & School of I…. Die Arbeit nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hebei Province.
Abstract (Originalsprache)
Cancer immunotherapies face limitations in treating “cold” tumors due to immune suppression driven by metabolic dysregulation within the tumor microenvironment. Research has revealed that tumor cells produce excess lactate via hypoxia‐induced glycolysis, promoting histone lactylation and establishing immunosuppression‐associated metabolic‐epigenetic reprogramming. Here, a near‐infrared (NIR)‐triggered nanoplatform (RgA‐L‐I/P/R) has been developed to fundamentally dismantle the immunosuppression via the metabolic‐epigenetic axis. Upon NIR excitation, the platform released oxygen from perfluoropentane (PFP) (“oxygen unlocking chamber”) in the tumor through dual targeting of AS1411 and Rg3 (“nano‐warhead”), liberating the IR‐1048 and the CRISPR/Cas9 ribonucleoprotein (RNP) (“NIR immune trigger” and “metabolic nanolock”). IR‐1048 induced immunogenic cell death (ICD) to trigger dendritic cell maturation and cytotoxic T lymphocyte infiltration, while CRISPR/Cas9 RNP induced LDHA (lactate dehydrogenase A) gene knockdown that locked the lactate supply and reprogrammed metabolism and epigenetics. These changes reduced histone lactylation and IL‐10 expression, promoting the conversion of tumor‐associated macrophages to the M1 type and synergistically downregulating hypoxia‐inducible factor‐1α (HIF‐1α) and programmed death‐ligand 1 (PD‐L1) expression upon oxygen release. This nanoplatform enables synergistic photothermal immunostimulation with CRISPR‐mediated metabolic and epigenetic reprogramming. Rather than merely countering mild downstream immune regulation by ICD, it seeks to fundamentally eliminate the immunosuppression, offering novel therapeutic strategies through the metabolic‐epigenetic pathway for poorly immunoresponsive tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Advanced Separation Membrane Materials, School of Chemistry & School of Electronics and Information Engineering & School of Integrated Circuits & School of Chemical Engineering and Technology & S…
- Key Laboratory for Tibet Plateau Phytochemistry of Qinghai, College of Pharmacy, Qinghai Minzu University, Xining, P.R. China.
- Key Laboratory of Catalysis and Energy Materials Chemistry (MOE) & Hubei Key Laboratory of Catalysis and Materials Science, School of Chemistry and Materials Science, South-Central Minzu University, Wuhan, P.R. China.
ORCID-Profile: Ziqun Chen, Jiang Wu, Yi Liu, Yujiao Liu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hebei Province
Zitieren
APA
Chen, Z., Guo, Z., Du, H., Liu, T., Shi, Q., Yang, Y., Wu, J., Liu, Y., & Liu, Y. (2026). Inhibiting Lactylation‐Mediated Metabolic‐Epigenetic Reprogramming to Potentiate Tumor Photo‐Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71955
Vancouver
Chen Z, Guo Z, Du H, Liu T, Shi Q, Yang Y, et al. Inhibiting Lactylation‐Mediated Metabolic‐Epigenetic Reprogramming to Potentiate Tumor Photo‐Immunotherapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71955
BibTeX
@article{Chen2026,
author = {Chen, Ziqun and Guo, Zhibin and Du, Haotian and Liu, Tingting and Shi, Qi and Yang, Yahui and Wu, Jiang and Liu, Yi and Liu, Yujiao},
title = {Inhibiting Lactylation‐Mediated Metabolic‐Epigenetic Reprogramming to Potentiate Tumor Photo‐Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71955}
}
EUVIMED